Clinuvel Pharmaceuticals (ASX:CUV) anticipates the receipt of Health Canada's marketing authorization decision for its drug candidate Scenesse for the treatment of vitiligo in the second half of 2026, according to a Monday Australian bourse filing.
The company also expects to report top-line preclinical results from its controlled-release liquid injectable platform candidate, VLRX-L, study in the first half, the filing said.
The company's shares shed about 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.